NCCN Guidelines® Insights - Prostate Cancer, Version 1.2021
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. This article summarizes the panel’s discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Category
  • Prostate Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Metastatic Castration-Resistant Prostate Cancer
Data on the use of systemic therapies for patients with metastatic CRPC is rapidly evolving, and clinicians need to be informed about the most recent clinical trial results, FDA approvals, and updates to the NCCN Guidelines for Prostate Cancer so that they can provide optimal care to their patients.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation